These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 27288217

  • 1. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
    Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW.
    Vaccine; 2016 Jul 19; 34(33):3810-6. PubMed ID: 27288217
    [Abstract] [Full Text] [Related]

  • 2. A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
    Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW.
    Pediatr Infect Dis J; 2017 Feb 19; 36(2):209-215. PubMed ID: 27846055
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R, PRI02C study group.
    Vaccine; 2017 Jun 27; 35(30):3764-3772. PubMed ID: 28583305
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 27; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 7. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
    Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S.
    Vaccine; 2017 Jan 11; 35(3):452-458. PubMed ID: 27939054
    [Abstract] [Full Text] [Related]

  • 8. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule.
    Martinón-Torres F, Salamanca de la Cueva I, Horn M, Westerholt S, Bosis S, Meyer N, Cheuvart B, Virk N, Jakes RW, Duchenne M, Van den Steen P.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2342630. PubMed ID: 38687024
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants.
    Marshall GS, Adams GL, Leonardi ML, Petrecz M, Flores SA, Ngai AL, Xu J, Liu G, Stek JE, Foglia G, Lee AW.
    Pediatrics; 2015 Aug 31; 136(2):e323-32. PubMed ID: 26216331
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study.
    Berner R, Boisnard F, Thomas S, Mwawasi G, Reynolds D.
    Vaccine; 2012 Jul 27; 30(35):5270-7. PubMed ID: 22691430
    [Abstract] [Full Text] [Related]

  • 11. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, Bernaola E, Diez-Domingo J, Carmona A, Sidhu M, Sarkozy DA, Gruber WC, Emini EA, Scott DA, 3007 Study Group.
    Pediatr Infect Dis J; 2012 Apr 27; 31(4):392-9. PubMed ID: 22301472
    [Abstract] [Full Text] [Related]

  • 12. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B.
    Pediatr Infect Dis J; 2017 Nov 27; 36(11):e272-e282. PubMed ID: 28719500
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.
    Sanchez L, Rungmaitree S, Kosalaraksa P, Jantarabenjakul W, Leclercq J, Yaiprayoon Y, Midde VJ, Varghese K, Mangarule S, Noriega F.
    Pediatr Infect Dis J; 2023 Aug 01; 42(8):711-718. PubMed ID: 37257121
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B, Halperin SA, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee AW, Li M, Tomovici A.
    Pediatr Infect Dis J; 2013 Jan 01; 32(1):54-61. PubMed ID: 23241989
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.
    Clin Vaccine Immunol; 2010 Jun 01; 17(6):1017-26. PubMed ID: 20427630
    [Abstract] [Full Text] [Related]

  • 16. Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series.
    Oliver JL, Sadorge C, Boisnard F, Snape MD, Tomlinson R, Mann R, Rudd P, Bhakthavalsala S, Faust SN, Heath PT, Hughes SM, Borrow R, Thomas S, Finn A.
    Vaccine; 2020 Jul 31; 38(35):5718-5725. PubMed ID: 32654902
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 31; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
    Prymula R, Kieninger D, Feroldi E, Jordanov E, B'Chir S, DaCosta X.
    Pediatr Infect Dis J; 2018 Aug 31; 37(8):823-830. PubMed ID: 29762363
    [Abstract] [Full Text] [Related]

  • 19. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
    Lee AW, Jordanov E, Boisnard F, Marshall GS.
    Expert Rev Vaccines; 2017 Feb 31; 16(2):85-92. PubMed ID: 27996332
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
    Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P.
    Eur J Pediatr; 2002 Nov 31; 161(11):581-7. PubMed ID: 12424582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.